DECHENG CAPITAL LLC
Q3 2026 Form 13-F

MENLO PARK, CAYMAN ISLANDS
CIK 0002010850 · CRD 293073 · SEC-registered investment adviser
$685.1M Reported Value Total

DC GLOBAL VENTURES reports 10 total accounts under management (AUM). There are 10 discretionary accounts valued at $2,728,192,342, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
8 funds · $2.7B gross asset value
Venture Capital Fund: $2.5B · Hedge Fund: $228.2M
Source: Form ADV filed 2026-03-31
Reported value
$685.1M
Quarter over quarter
-4.0%
Holdings
11
Top-10 concentration
99.9%

Key People

Form ADV owners & control persons
Xiangmin Nmn Cui
MANAGING DIRECTOR
Hongbo Nmn Bao
CHIEF COMPLIANCE OFFICER
Yuheng Nmn Qiu
CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 13, 2026
Form 13F-HR
Reported value $685.1M
Positions 11
Change in reported value -6.4%
New positions 0
Exited positions 3
Position turnover 21.4%
Top-10 concentration 99.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
11 $685.1M
Q2 2026 13F
Filed Aug 14, 2026
14 $731.7M
Q1 2026 13F
Filed May 13, 2026
14 $661.3M
Q4 2025 13F
Filed Feb 12, 2026
19 $743.4M
Q3 2025 13F
Filed Nov 14, 2025
23 $573.2M
Q2 2025 13F
Filed Aug 13, 2025
25 $396.0M
Q1 2025 13F
Filed May 8, 2025
27 $356.5M
Q4 2024 13F
Filed Feb 14, 2025
28 $466.2M
Q3 2024 13F
Filed Nov 15, 2024
26 $422.2M
Q2 2024 13F
Filed Aug 14, 2024
24 $326.3M
Q1 2024 13F
Filed May 14, 2024
22 $745.6M
Q4 2023 13F
Filed Feb 12, 2024
24 $357.9M

Top 11 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 CGON CG ONCOLOGY INC $451.7M 65.93%
2 NUVB Nuvation Bio Inc. $145.3M 21.22%
3 ACRS Aclaris Therapeutics, Inc. $21.3M 3.1%
4 AARD AARDVARK THERAPEUTICS INC $20.6M 3.01%
5 UPB Upstream Bio Inc. $14.4M 2.1%
6 RCUS Arcus Biosciences, Inc $11.0M 1.6%
7 EQ Equillium Inc. $7.2M 1.05%
8 LYELXXXX Lyell Immunopharma, Inc. $6.8M 0.99%
9 ZNTL Zentalis Pharmaceuticals Inc. $3.7M 0.54%
10 BYSI BeyondSpring Inc. $2.4M 0.34%
11 PYXS Pyxis Oncology, Inc (formerly Apexigen) $761.5K 0.11%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings